| Document |
Document Title |
|
WO/2008/057775A2 |
A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with th...
|
|
WO/2008/044767A1 |
Disclosed is a novel SCD inhibitor. The SCD inhibitor comprises a compound represented by the formula [I], a salt thereof, or a prodrug of the compound or the salt. wherein the ring A represents an aromatic ring which may be substituted;...
|
|
WO/2008/041100A1 |
Abstract The present invention more particularly relates to a process for the preparation of cephalosporin antibiotics of the Formula (I) wherein R1 represents hydrogen, trityl, alkyl like CH3, CRaRbCOORc where Ra and Rb independently re...
|
|
WO/2008/030902A1 |
Disclosed are sultam compounds of Formula (I) or a pharmaceutically-acceptable salt thereof. Also disclosed are methods of using such compounds in the treatment of at least one nuclear hormone receptor-associated condition, such as, for ...
|
|
WO/2008/022938A1 |
The present invention relates to compounds of the general Formula (I) wherein (A) is a 5 or 6-membered aromatic or heteroaromatic ring; R1 is cycloalkyl or is aryl or heteroaryl, wherein at least one ring is aromatic in nature, unsubstit...
|
|
WO/2008/021849A2 |
Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
|
|
WO/2008/017164A1 |
The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoar...
|
|
WO/2008/015005A2 |
The present invention relates to novel polymorphic forms of Ziprasidone sulfates Ziprasidone Hn+ X Z H2O wherein Ziprasidone is a compound of the formula; H is hydrogen; n is 1 or 2; 2- X is HSO4 - or SO4 2 -; and Z is O to 30., as well ...
|
|
WO/2008/007459A1 |
[PROBLEMS] To provide a 3,4-dihalogenoisothiazole derivative or a salt thereof which is not harmful to a crop and has a high controlling effect on an agricultural or horticultural plant disease such as rice blast disease, cucumber anthra...
|
|
WO/2008/006394A1 |
A process for the preparation of optically active (4E)-5-halo-2-alkylpent-4-enoic acids and their ester derivatives by a stereoselective synthesis which employs camphorsultam as chiral auxiliary is disclosed; in particular methyl (2S, 4E...
|
|
WO/2008/003800A1 |
The invention relates to derivatives of benzo[d]isothiazoles as histone deacetylase inhibitors, selected from among compounds having general formula (la) and (lb), one of the salts thereof, particularly one of the pharmaceutically-accept...
|
|
WO/2007/134085A2 |
Disclosed herein is a compound having a structure (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
|
|
WO/2007/129019A1 |
The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, 1 processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to thei...
|
|
WO/2007/129454A1 |
Disclosed is a 1,2-benzisothiazole derivative or a salt thereof which is not harmful to a crop and is remarkably effective on an agricultural or horticultural plant disease such as rice blast disease, wheat glume blotch, cucumber downey ...
|
|
WO/2007/125952A1 |
Disclosed is a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, or a solvate of any of them. (I) In the formula, R1 represents an optionally substituted lower alkyl group; Y represents -S(O)n- (w...
|
|
WO/2007/123186A1 |
A TLR signaling inhibitor, preferably an inhibitor of the production of various cytokines such as IL-8 or an inflammatory mediator, an inhibitor of the expression of COX-II or the like or an inhibitor of various kinases such as ATF2 cont...
|
|
WO/2007/116374A1 |
The invention relates to sulfonamide compounds of formula (I), where A, B, R3 and R4 are as defined in the claims, and their use as orexin receptor antagonists in the prevention and treatment of eating and drinking disorders, all types o...
|
|
WO/2007/113327A2 |
The present invention relates to N-cyclopropyl-sulfonylamide derivatives of formula (I) wherein the substituents are cyclic groups, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide...
|
|
WO/2007/113634A1 |
The present invention relates to novel compounds representated by formula (I), where R, R1, R2, R3, X, Y, m, n are as defined.The present invention relates to compounds of the general formula I their derivatives, their analogs, their tau...
|
|
WO/2007/114124A1 |
Disclosed is a compound represented by the formula below, a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt, which is useful as an inhibitor of 11β-hydroxysteroid dehydrogenase type I. wherein R1 repres...
|
|
WO/2007/112613A1 |
Methods for the preparation of N-substituted isothiazolinone derivatives are provided, which include reacting the N-substituted 3-mercaptopropionamide of formula II or N,N'-disubstituted 3,3'-dithiadipropionamide with sulfurylchloride, i...
|
|
WO/2007/113119A1 |
3-Amino-1,2-benzisothiazole compounds for combating animal pest The present invention relates to 3-amino-1,2-benzisothiazole compounds of formula (I) wherein R1, R2, R3, R4, R5 and n are defined in the description. The present invention ...
|
|
WO/2007/112669A1 |
The present invention relates to new dicyclooctane derivates represented by general formula (I), preparation processes and pharmaceutical compositions containing them, and to the uses for treatment especially for dipeptidyl peptidase inh...
|
|
WO/2007/094404A1 |
An optically active carboxylic acid compound can be produced by hydrolyzing an optically active acylated camphorsultam with an aqueous solution of an alkali earth metal hydroxide in the presence of a branched alkanol, whereby a correspon...
|
|
WO/2007/090752A1 |
Compounds of formula I processes for their preparation, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
|
|
WO/2007/087906A1 |
The present invention relates to N-cycloalkyl-benzyl-amide derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide active agents, particularly in the form of fun...
|
|
WO/2007/077889A1 |
Disclosed is a benzoisothiazoline compound represented by the formula (1), or a pest organism controlling agent comprising at least one of the compound as an active ingredient. (1) wherein A represents a hydrogen atom, a hydroxyl group, ...
|
|
WO/2007/061909A1 |
The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/o...
|
|
WO/2007/057407A2 |
The invention relates to insecticidal methods using 3-amino-1,2-benzoisothiazole compounds of the formula (I) wherein the variables n and R1 to R6 are as defined in the description. The invention relates to methods of combating or contro...
|
|
WO/2007/055928A1 |
E-metanicotine-type compounds that include a five-membered heteroaryl ring linked to an olefinic linker, such as a 4-penten-2-yl linker, which is linked to a terminal amine group, are disclosed. Patients susceptible to or suffering from ...
|
|
WO/2007/047474A2 |
Biphenyl derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.
|
|
WO/2007/043457A1 |
It is intended to provide a remedy or a preventive for hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy, diabetic retinitis and so on which has a non-nucleic acid structure and exerts an excellent xanthine oxidase in...
|
|
WO/2007/040986A1 |
Crosslinked polymeric materials are described that contain pendant amine capture groups. The amine capture groups include N-sulfonylaminocarbonyl groups that can react with amine-containing materials by a nucleophilic displacement reacti...
|
|
WO/2007/031146A1 |
Described is a process for preparing 3,4-dichloro-N-(2-cyanophenyl)-5-isothiazolecarboxamide, by a) reacting 3,4-dichloroisothiazole-5-carbonyl chloride with anthranilamide in the absence or the presence of an acid acceptor and b) then r...
|
|
WO/2007/030582A2 |
A compound of formula I wherein R1, R2, R3, R4 and R5 are described herein.
|
|
WO/2007/025585A1 |
A process for preparing 3,4-dichloroisothiazolecarboxylic acid of formula (I) is characterized in that in the first step of the process a cyanide, carbon disulphide and chlorine are reacted to the 3,4-dichloroisothiazolecarbonitrile of...
|
|
WO/2007/020460A1 |
This invention relates to a process for the preparation of compounds of formula (I) Where Ra, Rb, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are defined organic groups, the process comprising reactions a compound of formula (II) with a c...
|
|
WO2006125180B1 |
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I); where p, G, J, K, L, M, V, R2, R3,...
|
|
WO/2007/002214A2 |
There is provided a series of substituted acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2. R3, R4 and R5 as defined herein, their pharmaceutical compositions and methods of ...
|
|
WO/2007/002220A2 |
There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R2, R3, R4, R5, R25, R26 and R27 as defined herein, their pharmaceutical compositions and...
|
|
WO/2007/001932A2 |
This invention is directed to a compound of Formula (I), and pharmaceutically acceptable forms thereof useful as inhibitors of cPLA2 and a method for preventing, treating or ameliorating a cPLA2 mediated inflammatory related disease, dis...
|
|
WO/2006/136305A1 |
The invention relates to compounds of the formula (I), in which A, R1 , R2, R3, R4, R5, R6, R7 and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for ...
|
|
WO/2006/133417A1 |
The invention concerns compounds of formula (I) which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted- 3-hydroxy-5- arylamino-isothiazole-4-carboxamidines. Also included are the tautom...
|
|
WO/2006/125370A1 |
The present invention discloses a kind of aromatic ether compounds of general formula (I), in which the definitions of substituents are illuminated as description. The aromatic ether compounds of the present invention have broad spectrum...
|
|
WO/2006/125337A1 |
The present invention relates to &agr , β- and β, &gammad -unsaturated carboxylates and the use as herbicide thereof. The said compounds are shown below as general formula (I, II). Wherein: R1 is selected from C1-C4alkyl; R2 is selecte...
|
|
WO/2006/125208A1 |
The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas ...
|
|
WO/2006/111321A1 |
The invention relates to azole derivatives of formula (I) whose meanings are given in a description and to salts thereof which can be pharmaceutically used in the form of drags.
|
|
WO/2006/091858A1 |
The present invention relates to benzisothiazoles and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the benzisothiazoles and pharmaceutica...
|
|
WO/2006/077217A1 |
The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or -COO-C1-C4-alkyl group; Y represents NH, N-C1-C10-alkyl, O, or S; X represents O, S, NH, N-C...
|
|
WO/2006/073366A1 |
The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) &agr (NR1H3) and/or β (NR1H2) ...
|
